Insulin- und Adrenalinwirkung auf den Blutzucker während der Verdauungsperiode nach Versuchen an angiostomierten Hunden

Ohne Zusammenfassung     

Zur Pathologie des Zwischenhirns und der Hypophyse

Ohne ZusammenfassungZum Schluß können wir nicht umhin, dem Herrn Prof.A. M. Grünstein unsern tiefgefühlten Dank auszusprechen für seine liebenswürdige Anleitung bei der Ausführung der vorliegenden Arbeit, wie auch Herrn Dr.W. R. Meyer für die ausgeführte Sektion und für die Unterstützung bei der Erforschung der mikroskopischen Präparate.     

Validation of a computerized version of the scans questionnaire

Forty-seven subjects were administered two forms of the SCANS questionnaire (Slade & Dewey, 1986), an automated version and the standard pencil and paper format, in random order. The automated version was shown to correlate highly with the standard version. It is suggested that the use of a computerized version provides an alternative administration format with some advantages.     

Ulotaront: A TAAR1 Agonist for the Treatment of Schizophrenia

Ulotaront (SEP-363856) is a trace-amine associated receptor 1 (TAAR1) agonist with 5-HT1A receptor agonist activity in Phase 3 clinical development, with FDA Breakthrough Therapy Designation, for the treatment of schizophrenia. TAAR1 is a G-protein-coupled receptor (GPCR) that is expressed in cortical, limbic, and midbrain monoaminergic regions. It is activated by endogenous trace amines, and is believed to play an important role in modulating dopaminergic, serotonergic, and glutamatergic circuitry. TAAR1 agonism data are reported herein for ulotaront and its analogues in comparison to endogenous TAAR1 agonists. In addition, a human TAAR1 homology model was built around ulotaront to identify key interactions and attempt to better understand the scaffold-specific TAAR1 agonism structure–activity relationships.     

Acute myeloid leukemia: negative prognostic impact of early blast persistence can be in part overcome by a later remission prior to post-induction therapy

In acute myeloid leukemia, there is an ongoing debate on the prognostic value of the early bone marrow assessment in patients receiving intensive therapy. In this retrospective study, we analyzed the prognostic impact of the early response in 1,008 patients with newly diagnosed acute myeloid leukemia, who were treated at our institution with intensive chemotherapy followed by consolidation chemotherapy and/or allogeneic hematopoietic stem cell transplantation (HSCT). We found that early blast persistence has an independent negative prognostic impact on overall survival, event-free survival and relapse-free survival. This negative prognostic impact may only be overcome in patients showing at least a partial remission at the early bone marrow assessment and who subsequently achieve blast clearance by additional induction chemotherapy prior to consolidation therapy with allogeneic HSCT. In accordance, we propose that the time slope of remission is an additional leukemia-related dynamic parameter that reflects chemosensitivity and thus may inform post-induction therapy decision-making. In addition to patient-related factors, European LeukemiaNet risk group, measurable residual disease monitoring and donor availability, this may particularly apply to European LeukemiaNet intermediate-risk patients, for whom a decision between consolidation chemotherapy and allogeneic HSCT remains challenging in many cases.